2025-10-24 - Analysis Report
Okay, here's a report analyzing UNH (UnitedHealth Group Inc.) based on the data you've provided.

```
## UNH (UnitedHealth Group Inc.) Analysis Report

**Company Overview:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services.

**1. Performance vs. S&P 500 (VOO):**

*   **Cumulative Return:**
    *   UNH: -17.13%
    *   VOO: 99.09%
*   **Absolute Divergence:** -114.1% (UNH significantly underperforming VOO)
*   **Relative Divergence:** 9.9 (Indicates UNH's underperformance is near the lower end of its historical range relative to VOO).

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 54.0%  | 72.9% | 26.0%  | -0.1  | 197.0  |
| 2016-2018  | 43.0%  | 70.3% | 28.0%  | -0.2  | 222.6  |
| 2017-2019  | 37.0%  | 73.7% | 15.0%  | 0.2   | 262.7  |
| 2018-2020  | -41.0% | 81.6% | -65.0% | 0.7   | 313.3  |
| 2019-2021  | 17.0%  | 81.6% | -30.0% | 2.0   | 448.6  |
| 2020-2022  | 0.0%   | 81.6% | 1.0%   | 2.1   | 473.7  |
| 2021-2023  | 25.0%  | 80.5% | 23.0%  | 0.4   | 470.4  |
| 2022-2024  | -26.0% | 79.0% | -47.0% | 0.3   | 452.0  |
| 2023-2025  | -58.0% | 79.0% | -122.0%| 0.1   | 326.4  |

**Analysis of Alpha/Beta Table:**

*   **Recent Underperformance:**  The later years (especially 2018-2020, 2019-2021, 2022-2024, and 2023-2025) show significantly negative Alpha, indicating underperformance compared to the benchmark after adjusting for risk (Beta). The negative Alpha in recent years is a major concern.
*   **Increasing Beta:** Beta has generally increased over time, suggesting the stock's volatility relative to the market has grown.
*   **Decreasing CAGR:** The Compound Annual Growth Rate (CAGR) has decreased significantly in recent periods.
*   **High MDD:** Maximum Drawdown (MDD) remains high, indicating significant potential for losses.
*   **Cap:** Cap(B) reflects Market Cap which has been decreasing.

**2. Recent Price Action:**

*   **Current Price:** 365.37
*   **Last Market Data:** Price: 360.45, Previous Close: 361.49, Change: -0.29
*   **Moving Averages:**
    *   5-day MA: 360.85
    *   20-day MA: 356.05
    *   60-day MA: 318.77

**Analysis of Price Action:**

*   The price is above the 5-day, 20-day, and 60-day moving averages, suggesting a short-term upward trend.
*   The "Last-market" data indicates a slight decline, but the current price is higher, indicating a potential recovery.

**3. Indicators and Expected Return:**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 64.26 (Approaching overbought territory)
*   **PPO (Percentage Price Oscillator):** -0.36 (Bearish, but close to zero)
*   **Hybrid Signal:** Cash 80% / Sell 79.9% of holdings (Indicates a risky outlook, suggesting a high cash position).
*   **Recent Relative Divergence Change:** -1.9 (Short-term downward trend relative to the benchmark).
*   **Expected Return:** -135.0% (Very Poor Expectation: Expected underperformance vs S&P 500 over a 2+ year investment horizon).
*   **Last-market:** price decrease {'price': 360.45, 'previousClose': 361.49, 'change': -0.29}

**Analysis of Indicators:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is approaching overbought levels, indicating the stock might be due for a pullback.
*   The PPO is slightly negative, signaling bearish momentum.
*   The very high negative Expected Return is the most concerning indicator, suggesting significant potential underperformance.

**4. Recent News & Significant Events:**

*   Several news items revolve around UnitedHealth's Q3 earnings, including analyst projections and Warren Buffett's stake.
*   One article discusses rising medical costs and Obamacare concerns affecting Molina Healthcare.
*   BMO launched new CDRs including UnitedHealth, expanding Canadian investor exposure.

**Analysis of News:**

*   The focus on Q3 earnings suggests that the market is closely watching UnitedHealth's upcoming performance.
*   The article regarding Molina Healthcare could indirectly impact sentiment towards the healthcare sector as a whole.
*   The BMO CDR launch is a positive sign of increased investor accessibility.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.93)
*   **Target Price:** Average: 360.84 / High: 440.00 / Low: 198.00

**Analysis of Analyst Opinions:**
*   Analysts generally have a "Buy" rating on UNH.
*   The average target price is very close to the current price, suggesting limited near-term upside potential according to analysts.
*   The wide range between the high and low target prices indicates significant uncertainty about the stock's future performance.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-11 | 3.76 | 111.62 B$  |
| 2025-05-07 | 6.9  | 109.58 B$  |
| 2024-11-04 | 6.56 | 100.82 B$  |
| 2024-08-09 | 4.58 | 98.86 B$   |
| 2025-08-11 | 4.58 | 98.86 B$   |

**Analysis of Earnings:**

*   Revenue generally increasing
*   EPS fluctuates.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2025-06-30 | \$111.62B   | 17.93%        |
| 2025-03-31 | \$109.58B   | 21.70%        |
| 2024-12-31 | \$100.81B   | 21.14%        |
| 2024-09-30 | \$100.82B   | 22.84%        |
| 2024-06-30 | \$98.86B    | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity      | ROE    |
|------------|-------------|--------|
| 2025-06-30 | \$94.72B   | 3.60%  |
| 2025-03-31 | \$95.04B   | 6.62%  |
| 2024-12-31 | \$92.66B   | 5.98%  |
| 2024-09-30 | \$94.53B   | 6.41%  |
| 2024-06-30 | \$89.36B   | 4.72%  |

**Analysis of Financials:**

*   **Revenue:** Revenue has generally been increasing.
*   **Profit Margin:** Profit margin has recently decreased
*   **Equity:** Equity is stable.
*   **ROE (Return on Equity):** ROE has decreased

**7. Overall Summary and Conclusion:**

UNH has experienced significant underperformance relative to the S&P 500 recently. While analyst ratings are generally positive, the company's recent financial performance and the market indicators suggest caution.

*   **Key Concerns:** The most concerning aspects are the negative Alpha (indicating underperformance relative to the benchmark), decreasing profit margin and ROE, and the very negative Expected Return, all point to potential underperformance.
*   **Potential Positives:** Revenue growth and Analyst consensus is buy
*   **Overall Recommendation:** Given the significant underperformance, negative expected return, and mixed signals from financial indicators, a cautious approach is warranted. Investors should closely monitor upcoming earnings reports and sector-specific news to reassess the investment thesis.
```
